Provider: BehaviorLive — via AVBCC
Take This Course →Including ethics, supervision, and topics like this one. New live CEU every Wednesday.
Join Free →This panel will explore how the oncology ecosystem is responding to growing payer scrutiny of therapies approved under FDA's accelerated approval pathway. As payers begin to push back even in oncology on therapies approved based on surrogate endpoints or limited clinical data, the need for timely, robust real-world evidence is becoming urgent. At the same time, traditional value-based agreements are evolving in response to new definitions of value, care delivery shifts, and ongoing cost pressures. The discussion will highlight where payers, providers, and manufacturers can align around smarter evidence generation and next generation contracting models that balance access, risk, and innovation. Key discussion topics: real-world evidence as a pre-launch planning priority, not just post-marketing support, how payers are responding to accelerated approvals in oncology today, examples of emerging contracting models that reflect clinical uncertainty and delivery model complexity, where stakeholder collaboration is most needed to sustain value-based oncology care.
| Certification Body | Credits | Type |
|---|---|---|
| BACB | 1 | General |
Greg Gregory is a recognized leader in market access, pricing, and commercialization strategy, with over 25 years of experience spanning biomedical research and strategic consulting. As Executive Vice President and Partner at Precision AQ, Greg drives growth and innovation by fostering collaboration across consulting, agency, and product solutions to deliver innovative, data-driven strategies that help biopharma companies navigate complex market challenges. Over the past decade, Greg has played a pivotal role in integrating advanced analytics into strategic solutions, addressing commercialization challenges with actionable insights that align strategy with execution. Before joining Precision AQ, Greg was instrumental in building Insight Strategy Advisors, a boutique consulting firm later acquired by Precision, where he helped establish its reputation for impactful market access strategies. Greg honed his expertise with the Commercial Excellence and Market Access teams at Campbell Alliance Group, now Syneos Health. Under Greg’s leadership, Precision AQ has earned recognition through industry awards as one of the top boutique consulting firms globally. A published and frequently cited author with over a thousand citations of his peer-reviewed work, Greg combines scientific expertise with strategic foresight to inform best practices and drive measurable outcomes for clients. Greg’s experience spans launching blockbuster therapies that achieve rapid market success, developing innovative access and pricing strategies for rare diseases, and driving multi-billion-dollar acquisitions through defensible pricing strategies—all while ensuring patients gain timely access to transformative therapies. Greg holds a PhD in Immunology & Molecular Pathogenesis from Emory University, a BS in Microbiology from the University of Rochester, and completed a postdoctoral fellowship at the Children’s Hospital of Philadelphia.
Dig into the research behind this topic — plain-English summaries written for BCBAs.
244 research articles with practitioner takeaways
224 research articles with practitioner takeaways
161 research articles with practitioner takeaways
You earn CEUs from a dozen different places. Upload any certificate — from here, your employer, conferences, wherever — and always know exactly where you stand. Learning, Ethics, Supervision, all handled.
No credit card required. Cancel anytime.
All behavior-analytic intervention is individualized. The information on this page is for educational purposes and does not constitute clinical advice. Treatment decisions should be informed by the best available published research, individualized assessment, and obtained with the informed consent of the client or their legal guardian. Behavior analysts are responsible for practicing within the boundaries of their competence and adhering to the BACB Ethics Code for Behavior Analysts.